Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Audio Summaries

Every issue of Journal of clinical oncology : official journal of the American Society of Clinical Oncology moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.

119 audio summariesNLM Catalog

Specialties

Journal of clinical oncology : official journal of the American Society of Clinical Oncology covers research in these specialties.

Recent summaries

The latest articles summarized from Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: ALNEO Phase II Trial (GOIRC-01-2020-ML42316).

Nov 20, 2026

The ALNEO phase II trial asked whether 8 weeks of neoadjuvant alectinib followed by surgery and adjuvant alectinib is active and feasible in treatment-naïve, potentially resectable stage III ALK-positive NSCLC. In 33 patients, the major pathologic response rate was 42% (primary endpoint, 95% CI 26-61%), with 12% achieving pathologic complete response and 85% proceeding to surgery, 86% of whom had R0 resection. Grade ≥3 adverse events occurred in 9% during neoadjuvant treatment and 27% during adjuvant therapy, supporting perioperative alectinib as a feasible and active strategy, though median survival endpoints were not yet reached.

Reach of State-Mandated Insurance Coverage for Fertility Preservation in Patients With Cancer.

Nov 20, 2026

This retrospective cohort study of 903 patients newly diagnosed with cancer at a NCI-designated center asked how many young patients are actually reached by California's state fertility preservation insurance mandate and whether social determinants of health predict eligibility. Only 18% were eligible, with most ineligibility driven by Medicaid coverage and ineligible commercial plans, and non-English-speaking patients were significantly less likely to be eligible (adjusted RR 0.36). The authors also found that insurers often inaccurately reported lacking coverage (28% of the time) and that benefit verification took a median of 45 minutes, concluding that the mandate excludes most at-risk patients and perpetuates disparities.

Effect of a Multidisciplinary Intervention on Fatigue in Lymphoma Survivors With Persistent Fatigue: A Randomized Controlled Trial (the REFUEL trial).

Nov 20, 2026

This randomized controlled trial (REFUEL) asked whether a 12-week multidisciplinary program combining patient education, exercise, cognitive-behavioral therapy, and nutritional counseling could reduce persistent fatigue in 150 lymphoma survivors compared with usual care. The intervention significantly lowered Chalder Fatigue Questionnaire scores at 3 months (between-group difference -3.5), with the benefit persisting at 6 months but no longer significant at 9 months. It also improved physical, role, and global quality of life at 3 months, though effects on social, emotional, and cognitive functioning were not significant.

Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Breast Carcinoma: 5-Year Results of the Multicenter, Randomized, Phase III IRMA Trial.

Nov 17, 2026

The IRMA trial asked whether external-beam accelerated partial-breast irradiation (38.5 Gy in 10 twice-daily fractions) gives local control noninferior to whole-breast irradiation in low-risk invasive breast cancer patients. In 3,309 randomized women followed for a median of 97.5 months, 5-year ipsilateral breast tumor recurrence was very low in both arms (1.0% APBI vs 0.8% WBI, HR 1.18). Because the upper confidence limit (2.20) crossed the prespecified noninferiority margin of 1.5, formal noninferiority was not demonstrated, though the authors conclude APBI is a reasonable alternative for selected low-risk patients given the small absolute difference (<0.2%).

Dasatinib Dose Optimization With Weekend Drug Holiday for Improved Tolerability in Chronic Myeloid Leukemia (DasaHIT): A German Chronic Myeloid Leukemia Alliance Randomized Trial.

Nov 13, 2026

The DasaHIT trial asked whether a reduced-exposure dasatinib schedule (100 mg daily for 5 days, then a 2-day weekend break) can maintain treatment response while improving tolerability in chronic-phase CML. In first-line patients, intermittent dosing was noninferior to standard daily dosing for major molecular remission at 24 months (78% vs 81%), but it was not noninferior in later-line patients, who had lower response rates. The intermittent schedule also showed a lower rate of pleural/pericardial effusion (8% vs 16%), a post hoc finding that suggests but does not confirm better tolerability.

Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index.

Nov 13, 2026

This study developed and externally validated the CHARGE index, a prognostic score for predicting progression-free survival in relapsed/refractory multiple myeloma patients receiving BCMA- or GPRC5D-directed bispecific T-cell engagers. Six readily available factors (high-risk cytogenetics, hyperferritinemia, anemia, early relapse, poor performance status, and prior BCMA-directed therapy) stratified patients into low-, intermediate-, and high-risk groups with median PFS of 21.8, 7.1, and 1.6 months, respectively, and these distinctions held in an independent cohort. The index offers a simple, validated tool to guide prognosis and identify patients at high risk of early treatment failure with bispecific T-cell engagers.

Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment Eras.

Nov 12, 2026

This population-based cohort study of 7,428 women diagnosed with Hodgkin lymphoma before age 36 in England and Wales (1954–2010) asked whether second cancer risks have declined with modern treatment and what this means for survivorship care. Women had an overall 3.3-fold excess of subsequent cancers, and solid cancer risk fell by 25% in recent treatment eras, a decline largely explained by reduced radiotherapy use and dose, while hematologic malignancy risk did not improve. Elevated risks, particularly for lung and breast cancer, persisted beyond 50 years of follow-up, supporting lifelong surveillance and targeted screening.

Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update.

Nov 10, 2026

This CSCO-ASCO guideline update asks how best to treat non-metastatic nasopharyngeal carcinoma (stage IB–III) with radiotherapy combined with chemotherapy, given new evidence since 2021. Based on a multidisciplinary review of randomized trials and meta-analyses, the Panel recommends MRI-guided IMRT with image guidance, selective target de-escalation after induction chemotherapy, cisplatin-based concurrent chemoradiotherapy, and gemcitabine-cisplatin or docetaxel-cisplatin-fluorouracil as preferred induction regimens, with metronomic capecitabine as an adjuvant option for higher-risk patients. For PD-1 inhibitors, which improve disease control but lack mature overall survival data, the Panel makes no recommendation for or against routine addition and advises individualized decisions.

To Be Loved.

Nov 10, 2026

This reflective piece by Abigail Driscoll, published in the Journal of Clinical Oncology, examines the difficulties of providing oncology care to incarcerated patients. Rather than presenting a study with a formal research question, the author focuses on the clinical and ethical challenges of this work while emphasizing the shared humanity between caregivers and patients.

Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline.

Nov 10, 2026

This CSCO and ASCO joint guideline addresses how to treat recurrent and/or metastatic nasopharyngeal carcinoma across first-line, maintenance, consolidation, salvage, and subsequent-line settings. The expert panel found that platinum-based chemotherapy plus a PD-1 inhibitor is the preferred first-line option for medically fit patients, followed by PD-1 maintenance for up to 2 years, with chemotherapy alone as an alternative when immunotherapy is unsuitable. Selected responders may receive oral maintenance chemotherapy or locoregional consolidation IMRT, and isolated locoregional recurrence may be treated with salvage surgery or re-irradiation, with subsequent-line options including chemotherapy, PD-1 inhibitors, and antibody-drug conjugates.

Listen to Journal of clinical oncology : official journal of the American Society of Clinical Oncology

14-day free trial. Every new article, summarized in ~3 minutes.